PUBLISHER: IMARC | PRODUCT CODE: 1561415
PUBLISHER: IMARC | PRODUCT CODE: 1561415
The global superdisintegrants market size reached US$ 416.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 733.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.3% during 2024-2032.
Superdisintegrants are modified disintegrants added in drug formulations to facilitate the breakup or disintegration of tablets or capsules into smaller particles. They assist in increasing the absorption of the drug and the solubility of active pharmaceutical ingredients (APIs) in the body, thereby reducing the disintegration time or oral solid dosage forms and enhancing their efficiency. They are utilized at a low level in the solid dosage form, generally 1- 10% by weight relative to the total weight of the dosage unit. Presently, they are available in synthetic and natural variants and used in many therapeutic areas, such as cardiovascular, infectious, hematological, neurological, gastrointestinal diseases, and inflammatory diseases.
Solid dosage medicines currently hold a significant share in the pharmaceutical industry. This, coupled with the rising number of people suffering from various age-related and chronic diseases, represents one of the key factors strengthening the growth of the market. Moreover, the extensive usage of superdisintegrants in the production of orally disintegrating tablets (ODTs) for antipsychotics, antidepressants, antimigraine, and sedatives is offering lucrative growth opportunities to industry investors. Apart from this, features like high compatibility, improved bioavailability, and efficient compressibility are catalyzing the demand for superdisintegrants worldwide. Additionally, leading players are considerably investing in product development and innovation of novel formulations to retain a competitive edge in the market. Besides this, stringent regulations are propelling the use of safer alternatives in the pharmaceutical industry, which is assisting in the wider acceptance of natural superdisintegrants around the world. Furthermore, the growing burden of neurological disorders, in confluence with the increasing popularity of telemedicine on account of the coronavirus disease (COVID-19) outbreak, is anticipated to impel the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global superdisintegrants market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, type, dosage form, and therapeutic areas.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Asahi Kasei Corporation, Ashland Global Specialty Chemicals Inc., Avantor Inc., BASF SE, Corel Pharma Chem, DFE Pharma GmbH & Co. KG, DuPont de Nemours Inc., JRS Pharma GmbH & Co. KG, Merck KGaA, Nippon Soda Co. Ltd., Roquette Freres and Sigachi Industries Limited.